drugset / Trial / NCT01992042

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

NCT01992042 ↗

Phase 2 Completed 33 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelTreatment

Summary

This research study provides a novel opportunity to examine the intra-prostatic tumour inhibitory effects of statins in men with prostate cancer undergoing surgery.

Timeline

Start
2014-02
Primary completion
2016-10
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvastatin Other / unclassified 40 mg —
Background Pimonidazole Diagnostic / imaging agent — —

Indications